Learning Objectives:
To review population-level data on the incidence of GN, the risk of cardiovascular disease and the risk of infections
To describe personalized risk stratification in IgAN and the use of proteinuria as a surrogate outcome in IgAN
Dr. Sean Barbour Bio:
I completed my internal medicine and nephrology training at the University of British Columbia (BC) in 2010. I subsequently did a three-year glomerulonephritis fellowship and Master of Science in clinical epidemiology at the University of Toronto. I am an Associate Professor with the UBC Division of Nephrology, with a clinical and research focus on glomerular diseases. I am the Medical Lead and Chair of the BC Renal Glomerulonephritis Committee and GN Registry. Through these positions, I am responsible for health policy and health services related to glomerular diseases in BC. My research focus is on clinical trials, health outcomes and health services delivery in glomerulonephritis, and using prediction modeling techniques to improve risk stratification in glomerular diseases. I am the Chair of the International IgA Nephropathy Network Research Group and hold multiple peer-reviewed grants, including from the Michael Smith Foundation for Health Research, the Kidney Foundation of Canada, and the Canadian Institutes of Health Research.
Негізгі бет Personalized Risk-based management of IgA Nephropathy
Пікірлер